Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Same-day start to antiretroviral treatment leads to faster HIV suppression in San Francisco

A programme at San Francisco General Hospital that offers antiretroviral therapy (ART) on the same day as HIV diagnosis led to a high rate of treatment uptake

Published
23 July 2015
By
Liz Highleyman
Africa: MSF Warns Successful Global HIV Response Will Require Bigger Emphasis On Adherence

New MSF report surveying lay counsellor policies across eight countries highlights major weaknesses for adherence support

Published
22 July 2015
From
AllAfrica
Next-generation maturation inhibitor BMS-955176 shows good antiviral activity in combination with atazanavir

The next-generation HIV maturation inhibitor BMS-955176 was well-tolerated and suppressed HIV viral load as well as standard antiretroviral therapy when used in a combination with atazanavir (Reyataz)

Published
22 July 2015
By
Liz Highleyman
Intermittent PrEP may be a robust strategy for anal sex – vaginal much less certain

The pharmacodynamics (drug absorption and elimination rates) of the two drugs that comprise Truvada may favour the efficacy of intermittent pre-exposure prophylaxis (PrEP) more than previously thought, at

Published
22 July 2015
By
Gus Cairns
IAS 2015: While “game-changing,” START trial draws “line in the sand” and sets “time a’ ticking” to stop preventable illnesses and death, calls for action are accompanied by questions of impact of inequities, obstacles

Study also showed that most commonly used measure — CD4 count does not give accurate projection of illness risk.

Published
21 July 2015
From
Science Speaks
START trial provides definitive evidence of the benefits of early HIV treatment

People who start antiretroviral therapy (ART) immediately after HIV diagnosis, while their CD4 cell count is still high, rather than waiting until it falls below 350 cells/mm3

Published
21 July 2015
By
Liz Highleyman
Non-daily PrEP regimens provide extra options, but adherence is often better with daily dosing

For some people in some settings, less frequent pre-exposure prophylaxis (PrEP) regimens with doses linked to sexual activity are feasible, with high numbers of sexual acts protected

Published
21 July 2015
By
Roger Pebody
Targets proliferate in HIV cure research

The Towards an HIV Cure two-day symposium has become a fixture in advance of the International AIDS Society conferences and this one featured a more varied range

Published
21 July 2015
By
Gus Cairns
Young woman stays undetectable for twelve years off treatment after early HIV therapy

The 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) heard today of a case where a young woman, who was infected with

Published
21 July 2015
By
Gus Cairns
European Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults

Bristol-Myers Squibb announced today that the European Commission has approved Evotaz (atazanavir 300mg and cobicistat 150mg) tablets in combination with other antiretroviral agents for the treatment of adults with HIV-1 without known mutations associated with resistance to atazanavir.

Published
20 July 2015
From
BMS press release

Filter by country